XML 32 R19.htm IDEA: XBRL DOCUMENT

Restructuring Charges	12 Months Ended
Restructuring Charges	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Charges On December 13, 2016, the Company announced a strategic restructuring plan that allows it to concentrate on the distribution of kits and systems to be utilized by research institutions, cancer centers, and clinical service facilities for research use around the world. This restructuring plan included a reduction in force and has been completed as of December 31, 2016. The Company incurred approximately $790,000 in restructuring charges, which has been included as a component of operating loss for the year ended December 31, 2016. Restructuring charges include approximately $358,000 of costs related to termination of employees, which is net of a $60,000 stock-based compensation expense reversal for certain terminated employees. The remaining restructuring charges of approximately $432,000 were related to the impairment of an abandoned software development project. Of the total restructuring expenses recorded, approximately $418,000 remains to be paid as of December 31, 2016 and is included in accrued liabilities on the Company’s consolidated balance sheet.